This is a non-interventional, observational study with an optional interventional biobanking activity. Liver metastases of patients undergoing partial hepatectomy will be sampled completely while respecting the orientation used for medical imaging, in order to correlate the histopathological growth patterns in a 3D-map with the imaging characteristics. The full pathological sampling will only use remnant tissue.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. ≥ 18 years old.
2. Patients with liver metastatic colorectal or breast carcinoma undergoing a surgical excision of the liver metastases
3. Therapy-naive patients as well as patients with neo-adjuvant therapy are eligible for inclusion
4. Willingness of the patient to participate in this study demonstrated by signed written informed consent
Exclusion Criteria:
1. Patients without MRI or CT of the liver prior to surgery
2. Time interval between medical imaging, CT and/or MRI is more than 12 weeks (nb: time interval is preferably less than 4 weeks but this is not an exclusion criterium)
3. Prior radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) on the liver metastasis that would be operated
Primary outcome measure(s)
Radiomics Analysis Pipeline The imaging analysis has been designed to predict the continuous proportion and spatial distribution of HGPs — 7 years Radiomics Analysis Pipeline The imaging analysis has been designed to predict the continuous proportion and spatial distribution of HGPs. CT will be the principal modality because it is routinely acquired in patients undergoing liver surgery and is more broadly available for subsequent validation. MRI will be analyzed in a complementary exploratory framework when anatomical sequences are available. Analyses will be performed at three linked spatial scales: (a) the entire metastasis and its concentric peritumoral environment; (b) localized CT patches corresponding to histologically mapped interface segments; and (c) the background liver as an organ-level biological context. Handcrafted radiomics, foundation-model embeddings and localized patch analysis will be used.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
